Vimarsana
Biggest News Aggregation in the World

Page 13 - Peter Lamb News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Peter Lamb. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Peter Lamb Today - Breaking & Trending Today

Millions more to be spent on temporary accommodation in Crawley - Vimarsana News

Millions more to be spent on temporary accommodation in Crawley

Plans to add £6m for temporary accommodation to Crawley Borough Council’s capital budget have been supported by members of the cabinet.

Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Fi - Vimarsana News

Exelixis Announces Preliminary Fourth Quarter and Full Year 2021 Financial Results, Provides 2022 Fi

— Corporate priorities for 2022 include initial readout of up to three cabozantinib pivotal trials; initiation of pivotal trial program for XL092; expansion of clinical programs for XL092, XB002 and XL102; and multiple new development candidates from small molecule and biologics programs —— Cabozantinib franchise ac...

Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript - Vimarsana News

Exelixis, inc (EXEL) Q3 2021 Earnings Call Transcript

EXEL earnings call for the period ending September 30, 2021.

Source: fool.com
Crawley to bid city status for Queen's platinum jubilee - Vimarsana News

Crawley to bid city status for Queen's platinum jubilee

CRAWLEY is exploring the possibility of applying for city status on the 75th anniversary of becoming a town.

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes - Vimarsana News

Exelixis and STORM Therapeutics Enter into Exclusive Collaboration and License Agreement to Discover and Develop Inhibitors of Novel RNA Modifying Enzymes

STORM to deliver small molecule ADAR1 clinical candidate compounds discovered using its proprietary RNA modifying enzyme drug discovery platform ALAMEDA, Calif. and CAMBRIDGE, England,